Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment
Copyright policy )Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment
Abstract Introduction Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic predisposition. As tamoxifen-induced reductions in percent mammographic density (PMD) have been linked to the risk and prognosis of breast cancer, we conducted a candidate gene study to investigate the association between germline CYP2D6 polymorphisms and PMD change. Methods Baseline and follow-up mammograms were retrieved for 278 tamoxifen-treated subjects with CYP2D6 metabolizer status (extensive (EM), heterozygous extensive/intermediate (hetEM/IM) or poor metabolizer (PM)). Logistic regression analyses were conducted comparing subjects who experienced >10% reduction in PMD to those who experienced ≤10% reduction or increase. Results After multivariate adjustment, PMD change was found to be significantly associated with the degree of CYP2D6 enzyme functionality (Ptrend = 0.021). Compared with EM, hetEM/IM and PM were 72% (95% confidence interval (CI): 0.10 to 0.79) and 71% (0.03 to 2.62) less likely to experience a >10% reduction, respectively. Conclusions Tamoxifen-induced change in PMD appears to have a genetic component.
- University of Tübingen Germany
- Karolinska Institute Sweden
- National University of Singapore Singapore
- Human Genetics Canada
- Department of Medical Epidemiology and Biostatistics Sweden
mammary gland, genotype, antineoplastic hormone agonists and antagonists, Risk Factors, genetic variability, middle aged, genetic polymorphism, genetics, Breast Density, Medicine(all), tamoxifen, breast tumor, adult, article, Middle Aged, Prognosis, Mammary Glands, aged, female, Treatment Outcome, risk factor, Cytochrome P-450 CYP2D6, Female, Research Article, mammographic density, Antineoplastic Agents, Hormonal, Genotype, mammography, congenital malformation, 610, Antineoplastic Agents, Breast Neoplasms, quantitative trait, breast cancer, Genetic, follow up, Humans, human, Polymorphism, Mammary Glands, Human, cytochrome P450 2D6, Aged, Polymorphism, Genetic, Hormonal, treatment response, major clinical study, body mass, Tamoxifen, enzyme polymorphism, treatment outcome, pathology, prognosis, metabolism
mammary gland, genotype, antineoplastic hormone agonists and antagonists, Risk Factors, genetic variability, middle aged, genetic polymorphism, genetics, Breast Density, Medicine(all), tamoxifen, breast tumor, adult, article, Middle Aged, Prognosis, Mammary Glands, aged, female, Treatment Outcome, risk factor, Cytochrome P-450 CYP2D6, Female, Research Article, mammographic density, Antineoplastic Agents, Hormonal, Genotype, mammography, congenital malformation, 610, Antineoplastic Agents, Breast Neoplasms, quantitative trait, breast cancer, Genetic, follow up, Humans, human, Polymorphism, Mammary Glands, Human, cytochrome P450 2D6, Aged, Polymorphism, Genetic, Hormonal, treatment response, major clinical study, body mass, Tamoxifen, enzyme polymorphism, treatment outcome, pathology, prognosis, metabolism
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!